Literature DB >> 22334838

Prevalence of endocrinopathies in patients with Beta-thalassaemia major - a cross-sectional study in oman.

Waad-Allah Mula-Abed, Huda Al Hashmi, Muhanna Al Muslahi, Hilal Al Muslahi, Mohammad Al Lamki.   

Abstract

BACKGROUND: Beta-thalassaemia major is a common medical problem worldwide. There is little data dealing with the nature and prevalence of different endocrine disorders in this disease in the Sultanate of Oman.
OBJECTIVES: To establish the prevalence and times of occurrence of endocrine disorders in patients with beta-thalassaemia major.
METHODS: This cross-sectional study was conducted during Jan-Jul 2008 and dealt with 30 Omani patients with transfusion-dependent homozygous beta-thalassaemia major who were consulting Thalassaemia Clinic, Royal Hospital. They included 15 males and 15 females, aged 16 to 32 years with median of 21 years and mean ± SD of 21.23 ± 3.42 years. The medical records of these patients were reviewed and their endocrine functions were assessed. This assessment included pituitary and gonadal function, thyroid function, bone profile (including Parathyroid Hormone), morning cortisol and fasting glucose. These profiles were reviewed to exclude hypogonadism, hypothyroidism, hypoparathyroidism, hypoadrenalism or diabetes mellitus.
RESULTS: Hypogonadism was reported in 22 (73.3%) patients (13 female, 9 male). Low levels of Follicle-Stimulating Hormone (FSH) and low Luteinizing Hormone (LH) with low estradiol (in females) or testosterone (in males) was noted in 15 (50.0%) patients (7 female, 8 male). Normal (but inappropriately low) levels of FSH and LH with low estradiol (in females) or testosterone (in males) was noted in 7 (23.3%) patients (6 female, 1 male). Primary hypothyroidism was present in only 1 (3.3%) patient (female) who Hypoparathyroidism was found in 3 (10.0%) patients (2 female, 1 male). Diabetes mellitus with high fasting glucose was noted in 8 (26.7%) patients (2 female, 6 male). Morning cortisol levels for all patients were within the reference range with no suspicion of hypoadrenal cortical function. Eight (26.7%) patients had no endocrine disorder, 12 (40.0%) patients had one disorder, 8 (26.7%) patients had 2 disorders, and 2 (6.7%) patients had 3 endocrine disorders. There was no significant difference (p>0.050) in mean serum ferritin in thalassaemics with or without endocrinopathy, regardless of the number of endocrinopathy.
CONCLUSION: There is high prevalence of endocrine disorders among Omani beta-thalassaemic adult patients. This signifies the importance of awareness for their development and monitoring for early detection and replacement therapy. No relationship between serum ferritin and development of endocrinopathy was noted.

Entities:  

Keywords:  Beta-thalassaemia; Endocrinopathy

Year:  2008        PMID: 22334838      PMCID: PMC3273922     

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  30 in total

1.  Insulin resistance and beta cell function in chronically transfused patients of thalassemia major.

Authors:  Jyoti Suvarna; Hemraj Ingle; C T Deshmukh
Journal:  Indian Pediatr       Date:  2006-05       Impact factor: 1.411

Review 2.  Beta-thalassaemia.

Authors:  S L Thein
Journal:  Baillieres Clin Haematol       Date:  1998-03

3.  Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion.

Authors:  C A Sklar; L Q Lew; D J Yoon; R David
Journal:  Am J Dis Child       Date:  1987-03

4.  A hematological survey of preschool children of the United Arab Emirates.

Authors:  Campbell J Miller; Earl V Dunn; Bertel Berg; Sameeh F Abdouni
Journal:  Saudi Med J       Date:  2003-06       Impact factor: 1.484

5.  Genetic Blood Disorders Survey in the Sultanate of Oman.

Authors:  Asya Al-Riyami; G J Ebrahim
Journal:  J Trop Pediatr       Date:  2003-07       Impact factor: 1.165

6.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

7.  Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.

Authors:  Patrick B Walter; Eric A Macklin; John Porter; Patricia Evans; Janet L Kwiatkowski; Ellis J Neufeld; Thomas Coates; Patricia J Giardina; Elliott Vichinsky; Nancy Olivieri; Daniele Alberti; Jaymes Holland; Paul Harmatz
Journal:  Haematologica       Date:  2008-05-10       Impact factor: 9.941

8.  Hemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in hospital births in Bahrain.

Authors:  A M Mohammed; F Al-Hilli; K V Nadkarni; G P Bhagwat; J P Bapat
Journal:  Ann Saudi Med       Date:  1992-11       Impact factor: 1.526

9.  Prevalence of beta-thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia.

Authors:  Ahmad Al-Suliman
Journal:  Ann Saudi Med       Date:  2006 Jan-Feb       Impact factor: 1.526

10.  Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.

Authors: 
Journal:  Clin Endocrinol (Oxf)       Date:  1995-06       Impact factor: 3.478

View more
  9 in total

1.  Indicators of Renal Glomerular and Tubular Functions in Patients with Beta-Thalassaemia Major: A cross sectional study at the Royal Hospital, Oman.

Authors:  Waad-Allah S Mula-Abed; Huda S Al-Hashmi; Muhanna N Al-Muslahi
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

2.  Endocrinal Complications in Children and Adolescents with Thalassemia Major in Central India: An Observational Study.

Authors:  Nandini Dixit; Chandan Kumar Shaw; Garima Agrawal Varshney; Ravindra Kumar; Purti Agrawal Saini; Pramila Verma
Journal:  Indian J Pediatr       Date:  2021-09-04       Impact factor: 5.319

3.  Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia.

Authors:  Murtadha Al-Khabori; Sunil Bhandari; Mohammed Al-Huneini; Khalil Al-Farsi; Vinodh Panjwani; Shahina Daar
Journal:  Oman Med J       Date:  2013-03

4.  Clinical and Biochemical Data of Adult Thalassemia Major patients (TM) with Multiple Endocrine Complications (MEC) versus TM Patients with Normal Endocrine Functions: A long-term Retrospective Study (40 years) in a Tertiary Care Center in Italy.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Christos Kattamis; Nada A Soliman; Rania Elalaily
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-12       Impact factor: 2.576

Review 5.  Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis study.

Authors:  Milad Azami; Ali Sharifi; Siros Norozi; Akram Mansouri; Kourosh Sayehmiri
Journal:  Caspian J Intern Med       Date:  2017

6.  Complications and Challenges in the Management of Iraqi Patients with β-Thalassemia Major: A Single-center Experience.

Authors:  Regir K Sadullah; Sulav D Atroshi; Nasir A Al-Allawi
Journal:  Oman Med J       Date:  2020-07-27

Review 7.  Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.

Authors:  Li-Na He; Wei Chen; Yi Yang; Ying-Jun Xie; Ze-Yu Xiong; Di-Yu Chen; Dian Lu; Neng-Qing Liu; Ying-Hong Yang; Xiao-Fang Sun
Journal:  Biomed Res Int       Date:  2019-04-18       Impact factor: 3.411

8.  Hypothyroidism and Hypoparathyroidism in Thalassemia Major Patients: A Study in Sistan and Baluchestan Province, Iran.

Authors:  Ali Bazi; Hadi Harati; Ali Khosravi-Bonjar; Elham Rakhshani; Mojtaba Delaramnasab
Journal:  Int J Endocrinol Metab       Date:  2018-02-10

9.  Detection of endocrine disorders in young children with multi-transfused thalassemia major.

Authors:  Ramadan A Mahmoud; Ashraf Khodeary; Marwa S Farhan
Journal:  Ital J Pediatr       Date:  2021-07-31       Impact factor: 2.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.